Search Results
Your search for all items matches 37049 pages
Showing 1 - 50FDA Approves Dostarlimab for MSI-H/dMMR Locally Advanced Rectal Cancer
On October 19, 2026, the U.S. Food and Drug Administration (FDA) granted an accelerated approval to the PD-1 inhibitor dostarlimab (Jemperli) for the treatment of adult patients with stage II/III locally advanced rectal cancer that is microsatellite instability–high (MSI-H) or mismatch repair...
Mocertatug Rezetecan Shows Early Activity in Platinum-Resistant Ovarian and Endometrial Cancers
First results from the global phase I BEHOLD-1 study suggest that the investigational B7-H4–targeted antibody-drug conjugate mocertatug rezetecan showed activity in two difficult-to-treat gynecologic cancers: platinum-resistant ovarian cancer and recurrent or advanced endometrial cancer.1 At the...
ASH Issues New Recommendations for the Management of Myelofibrosis
The American Society of Hematology (ASH) released new guidelines on the management of myelofibrosis which recommend expanded molecular testing, early transplant referral, appropriate use of JAK inhibitors, and aspirin therapy in select patients. The guidelines were published by Stein et al in Blood ...
Immunotherapy-Based Downstaging Linked to Improved Outcomes After Liver Transplantation in Hepatocellular Carcinoma
An immune checkpoint inhibitor–based multimodal downstaging strategy before liver transplantation was associated with improved posttransplant survival and a lower risk of recurrence among patients with hepatocellular carcinoma initially beyond the Milan criteria (single lesion not larger than 5 cm...
Novel Androgen Receptor Degrader Demonstrates Antitumor Activity in Advanced Prostate Cancer
The novel androgen receptor degrader bavdegalutamide demonstrated a manageable safety profile and antitumor activity in patients with metastatic castration–resistant prostate cancer previously treated with androgen receptor pathway inhibitors, particularly those with tumors harboring specific...
Phase III VERIFY Trial Demonstrates Benefits of Rusfertide in Polycythemia Vera
According to findings from the phase III VERIFY trial reported by Kuykendall et al in the Journal of Clinical Oncology, the addition of the hepcidin mimetic rusfertide to standard-of-care therapy significantly improved hematocrit control, reduced the need for phlebotomy, and improved...
Even Highly Curable Childhood Leukemias Take a Substantial Toll on Families, Study Finds
New research published by Rodwin et al in JNCCN—Journal of the National Comprehensive Cancer Network has found that families of children receiving treatment for B-cell acute lymphoblastic leukemia (ALL) experience substantial and lasting challenges beginning early after diagnosis, according to a...
Iberdomide Triplet Improves MRD-Negative Complete Response in Relapsed/Refractory Multiple Myeloma
Iberdomide combined with daratumumab and dexamethasone nearly doubled the rate of minimal residual disease (MRD)-negative complete response compared with daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma. Lonial et al reported the primary MRD...
ASCO 2026: Lung Cancer Specialist Apar Kishor Ganti, MD, Shares His Insights
The 2026 ASCO Annual Meeting featured numerous high-impact studies in lung cancer. To help readers identify the presentations with the greatest potential to influence clinical practice, The ASCO Post asked lung cancer specialist Apar Kishor Ganti, MD, MS, FASCO, to share his top picks. Dr. Ganti is ...
Two Studies Show Breast Cancer Survival and Mortality Gaps Are Widening Between Rural and Urban Areas
Survival and mortality disparities for women with breast cancer are widening between rural and urban areas over time, according to findings from two American Cancer Society studies presented at the 2026 ASCO Quality Care Symposium (Abstracts 208 and 253). The studies found that women from rural...
Amyloidosis: Novel Treatments Could Improve Poor Outcomes
Systemic light chain amyloidosis is a clonal plasma cell disorder that can lead to end-organ dysfunction, with no approved treatment in the relapsed/refractory setting. Given this challenging clinical situation, two studies of novel therapies for this disease reported at the 2026 ASCO Annual...
Chronic Immune-Related Adverse Events Common After Adjuvant Anti–PD-1 Therapy for Melanoma
Nearly half of patients with resected high-risk melanoma treated with adjuvant anti–PD-1 therapy developed chronic immune-related adverse events, and more than one-third still had ongoing toxicity after a median follow-up of more than 5 years. Roma A. Kankaria, MD, and colleagues reported the...
ASCO and WHO Formalize Partnership
Cancer is one of the leading causes of morbidity and mortality worldwide, affecting 92% of families around the world, according to the latest estimates from the World Health Organization (WHO) Global status report on cancer 2026. The highest health, social, and economic burdens occur in low- and...
Study Supports Universal Germline Genetic Testing Regardless of Age at Cancer Diagnosis
Universal germline genetic testing after an individual receives a cancer diagnosis may help to uncover hereditary cancer risks in the patient's family, according to findings published in Cancer Discovery. In a study of a pan–solid tumor cohort, researchers found enriched germline pathogenic...
FDA Approves Expanded Indication for Nogapendekin Alfa Inbakicept in BCG-Unresponsive NMIBC
On October 14, 2026, the U.S. Food and Drug Administration (FDA) approved the IL-15 receptor agonist nogapendekin alfa inbakicept-pmln (Anktiva) in combination with bacillus Calmette-Guérin (BCG) for the treatment of adults with BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC). This...
Facilitated Cascade Genetic Testing Improves Uptake Among Relatives of BRCA1/2 Variant Carriers
According to findings from a randomized controlled trial reported by Wilke et al in the Journal of Clinical Oncology, a clinician-facilitated approach to cascade genetic testing significantly increased genetic testing uptake among first-degree relatives of individuals with BRCA1 or BRCA2 pathogenic ...
Sitagliptin Added to Standard Prophylaxis Reduces Risk of Acute GVHD Following Alternative Donor Transplantation
Adding the selective, oral dipeptidyl peptidase-4 inhibitor, sitagliptin, to antithymocyte globulin–based prophylaxis significantly reduced the incidence of grade 2 to 4 acute graft-vs-host disease (GVHD) among patients undergoing alternative donor hematopoietic stem-cell transplantation, according ...
Automated vs Handheld Ultrasound for Breast Cancer Screening
A new study by Rauscher et al in the Journal of the American College of Radiology has found that automated breast ultrasound (ABUS) and handheld ultrasound (HHUS) had similar cancer detection rates in women with dense breasts, whereas ABUS had a lower false-positive rate. These data demonstrate...
ASCO Remembers Dr. Rachna T. Shroff, Expert in Gastrointestinal Cancers and Dedicated ASCO Volunteer
ASCO joins the oncology community in mourning the death of Rachna T. Shroff, MD, MS, FASCO, a renowned expert specializing in gastrointestinal (GI) cancers and a dedicated ASCO volunteer. Dr. Shroff passed away following a battle with an aggressive cancer. After completing her training, Dr....
Implementing Massage and Acupuncture to Achieve Better Pain Management in Oncology Care: An Overview of the IMAGINE Project
Pain is an incredibly challenging symptom that affects over 40% of patients with cancer in active treatment1 and up to two in three patients with advanced cancer.2 Analgesic pain medications including opioids have been the predominant pain management strategy; however, their use is limited by...
Anitocabtagene Autoleucel Shows High Response Rate in Heavily Pretreated Relapsed/Refractory Multiple Myeloma
Anitocabtagene autoleucel (anito-cel), an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, produced responses in all treated patients in a phase I study of heavily pretreated relapsed or refractory multiple myeloma, with 79% achieving a...
Remote Exercise Program Reduces Cancer-Related Fatigue, Improves Quality of Life for Patients Undergoing Immunotherapy
A supervised remote exercise program improved the quality of life of patients with cancer undergoing immunotherapy, primarily by reducing cancer fatigue, according to findings from a secondary analysis of a phase II trial that will be presented at the 2026 ASCO Quality Care Symposium (Abstract...
Financial Navigation Support May Help Reduce Financial Toxicity for Some People With Advanced Cancer
Results from the randomized nationwide CREDIT trial showed that a financial navigation support program does not broadly reduce financial hardship for people being treated for advanced cancer. However, it can help a subgroup of people: those with existing financial and social resources that make...
The Wistar Institute Names New President and Chief Executive Officer
The Wistar Institute’s Board of Trustees has appointed Ronny Drapkin, MD, PhD, a physician-scientist and ovarian cancer researcher at the University of Pennsylvania Perelman School of Medicine, to be the Institute’s next President and Chief Executive Officer, effective November 30, 2026. Dr....
Early Research Links Abdominal Obesity to Increased Lung Cancer Risk
Findings from a recent study published in the Journal of Thoracic Oncology challenge the idea that an obesity paradox contributes to reduced lung cancer risk—instead, the data suggested that obesity may be associated with enhanced lung carcinogenesis. “Overall, our data clearly associate central ...
HER2-Negative Advanced Gastric Cancers: First-Line Retlirafusp Alfa Combination Demonstrates Survival Benefit
The addition of retlirafusp alfa to capecitabine and oxaliplatin (CAPOX) significantly prolonged overall survival compared with chemotherapy alone as first-line treatment for patients with unresectable, locally advanced or metastatic, HER2-negative gastric or gastroesophageal junction...
Study Identifies Insurance and Cost Barriers to Oral Therapies for Blood Cancers
A nationwide study of patients with blood cancers found that most prescriptions for specialty oral anticancer medications were initially rejected by insurers, and many patients did not fill their prescriptions even after receiving approval. The findings, reported by Doshi et al in the Journal of...
Neil M. Iyengar, MD, on Co-Occurring Mutations in Advanced Breast Cancer: Management Strategies
In hormone receptor–positive, HER2-negative metastatic breast cancer, co-occurring ESR1 and PIK3CA mutations create therapeutic complexity. Oral SERDs, including elacestrant, retain activity despite PIK3CA co-mutation and may offer an efficacy–toxicity balance compared with PI3K/AKT pathway...
Neil M. Iyengar, MD, on Testing for ESR1 Mutations in ER-Positive Breast Cancer
ESR1 mutations are a major mechanism of acquired endocrine resistance in hormone receptor–positive metastatic breast cancer and are associated with poorer outcomes. Serial ctDNA testing enables dynamic detection of emergent ESR1 mutations and clonal evolution, potentially informing treatment...
Matthew Lunning, DO, FACP: How Does CAR T-Cell Therapy Factor in With Tafasitamab in DLBCL?
Access to second-line chimeric antigen receptor (CAR) T-cell therapy remains suboptimal in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Matthew Lunning, DO, FACP, of the University of Nebraska Medical Center, explains that prior tafasitamab exposure may theoretically affect CD19...
Matthew Lunning, DO, FACP, on DLBCL: Are frontMIND Data Top of Mind?
The phase III frontMIND trial demonstrated improved outcomes vs R-CHOP in high-risk patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), paralleling the POLARIX trial. Despite efficacy, tafasitamab/lenalidomide/R-CHOP has not achieved comparable guideline adoption. Uncertainty...
FDA Approves Atezolizumab in Combination With Chemotherapy for Stage III dMMR Colon Cancer
On October 8, the U.S. Food and Drug Administration (FDA) approved atezolizumab (Tecentriq) in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of adult and pediatric patients aged 2 years and older with stage III mismatch repair–deficient (dMMR) colon cancer. The FDA...
Robotic Esophagectomy Improves Lymph Node Yield in Esophageal Cancer
According to results from the phase III ROBOT-2 trial published in JAMA Surgery, robot-assisted minimally invasive esophagectomy provided a more radical lymphadenectomy than conventional minimally invasive esophagectomy in patients with esophageal or esophagogastric junction adenocarcinoma. Berlth...
Starting Surveillance Colonoscopy After High-Risk Adenoma Removal: When Is the Right Time?
Surveillance colonoscopy at 5 years after removal of high-risk adenomas was noninferior to surveillance at 3 years in terms of colorectal cancer incidence during the first 5 years after adenoma removal, according to an interim analysis of the randomized EPoS II trial reported by Jover et al in The...
ACS Report Highlights Cancer Burden and Screening Disparities in U.S. Hispanic Population
The cancer distribution in the Hispanic population is distinct from the general population in the United States, according to a statistics report from the American Cancer Society (ACS) published in CA: A Cancer Journal for Clinicians. The report indicated fewer lung and urinary bladder cancers,...
Study Supports Sentinel Lymph Node Biopsy After Chemotherapy in Locally Advanced Breast Cancer
A prospective study found that sentinel lymph node biopsy may be an accurate method of axillary staging in selected patients with locally advanced breast cancer who achieve a clinical nodal response to neoadjuvant chemotherapy—potentially allowing some patients to avoid axillary lymph node...
Charles M. Perou, PhD, Honored With 2026 William L. McGuire Memorial Lecture Award
Charles M. Perou, PhD, will receive the William L. McGuire Memorial Lecture Award during the San Antonio Breast Cancer Symposium 2026 (SABCS), to be held December 8 to 11 at the Henry B. González Convention Center in San Antonio, Texas. He will present his award lecture, titled “Quantitative...
HER2-Positive Breast Cancer: FDA Approves Triplet for Maintenance Therapy
On October 7, the U.S. Food and Drug Administration (FDA) approved tucatinib (Tukysa), a HER2-targeted tyrosine kinase inhibitor, in combination with trastuzumab and pertuzumab for the maintenance treatment of adult patients with unresectable locally advanced or metastatic HER2-positive breast...
GLP-1 Receptor Agonist Use Linked to Lower Colorectal Cancer Risk in Patients With Inflammatory Bowel Disease
Use of GLP-1 receptor agonist was significantly associated with a lower 5-year incidence of colorectal cancer among patients with inflammatory bowel disease (IBD), including those with concomitant type 2 diabetes, according to findings presented at the 2026 ASCO Breakthrough Meeting in Singapore.1...
Pediatric Bone Sarcoma Gets First NCCN Guidelines
The National Comprehensive Cancer Network (NCCN) has released its first-ever NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for pediatric bone sarcomas. These new guidelines offer a comprehensive set of treatment recommendations for a challenging pediatric cancer, and offer...
2026 Albany Prize Awardees Announced
Tony Hunter, PhD, and Dennis J. Slamon, MD, PhD, have been awarded the 2026 Albany Medical Center Prize in Medicine and Biomedical Research. The two distinguished recipients are being recognized for their breakthrough discoveries that have revolutionized our understanding of the molecular...
Residual Ovarian Cancer Risk in BRCA Carriers May Inform Timing of Preventive Surgery
Among older BRCA carriers who remain in good health, the residual risk of ovarian cancer may be high enough to support consideration of preventive surgery, according to findings from a prospective cohort study reported in JAMA Surgery. Giannakeas et al also found that BRCA1 carriers who defer...
Replacing Intensive Chemotherapy With Blinatumomab Improves Outcomes in High-Risk Pediatric Acute Lymphoblastic Leukemia
Replacing two cycles of intensive chemotherapy with blinatumomab significantly improved event-free survival in children with newly diagnosed high-risk B-cell acute lymphoblastic leukemia (ALL), while also reducing several serious treatment-related toxicities. Schrappe et al reported results from...
Pedro Rocha, MD, PhD, on Extensive-Stage SCLC: Subcutaneous Tarlatamab
Pedro Rocha, MD, PhD, of Vall d'Hebron University Hospital, presents data from the phase Ib DeLLphi-308 study, which investigated subcutaneous administration of the bispecific T-cell engager tarlatamab—which may improve convenience and produce lower peak serum concentrations, potentially reducing...
The Molecular Watchman: Why Measurable Residual Disease Testing Is Redefining Treatment and Surveillance in Colorectal and Bladder Cancers
Implementing a personalized medicine approach in oncology increasingly includes the use of measurable residual disease (MRD) testing to detect molecular evidence of cancer that remains after treatment, enabling more precise risk stratification, earlier intervention, and more informed treatment...
Pediatric and Adolescent Colorectal Carcinoma: A Retrospective Analysis
Rates of advanced-stage colorectal cancer are climbing in young patients, marking a need for increased vigilance, according to data presented during the American Academy of Pediatrics 2026 National Conference & Exhibition (Abstract 02-204). Investigators retrospectively examined the medical...
Tile-Based Radiation Outperforms Postoperative Stereotactic Radiation Therapy in Resected Brain Metastases
According to findings from a phase III trial reported by Weinberg et al in the Journal of Clinical Oncology, intraoperative tile-based radiation therapy with cesium-131 significantly improved surgical bed control compared with postoperative stereotactic radiation therapy in patients undergoing...
AI-Extracted Chart Data for Expanding Surgical Oncology Learnings
Large language models (LLMs) are capable of extracting structured data directly from electronic medical records, expanding data sets available for research, training, and developing artificial intelligence (AI) models. In a session on operating rooms of the future at Cleveland Clinic’s A.I. Summit...
Wildfire-Related Fine Particulate Matter Linked to Higher Mortality in Older Patients With Lung Cancer
Long-term exposure to fine particulate matter from wildfire smoke was associated with a higher risk of death among older patients with lung cancer, and wildfire-related particulate matter appeared more harmful than nonwildfire air pollution at the same exposure level. Zhang et al reported the...
Global Gaps in Cancer-Control Expenditure Data Identified
There is a large global gap in expenditure data on cancer control, and available data suggest generally low and unequal expenditure across countries and territories, according to a cross-sectional analysis published by Figi et al in The Lancet �Oncology. “The paucity of publicly available...
